Q3 2025 earnings call: brepocitinib Phase II wins, Phase III plans, 2026 catalysts, $4.5B cash & Moderna trial—read key insights.

Highlights from Boston’s premier design event, featuring innovative interiors, trends, and standout spaces.

This article has been disseminated on behalf of LaFleur Minerals Inc. and may include a paid advertisement.NEW YORK, Jan. 22, 2026 (GLOBE ...

This facility received the Renovations Silver award in the 2025 Firehouse Station Design Awards. Find the full list of winners here. The Beacon Fire Department, which historically was a volunteer-led ...

Beam Therapeutics (NASDAQ:BEAM) is one of the most promising mid-cap healthcare stocks under $50. On December 9, H.C. Wainwright analyst Patrick Trucchio reaffirmed his bullish stance on Beam ...

Oncology clinical trials drive some of the most important advances in medicine, yet they remain some of the most challenging to design and run. Intensive assessments, frequent amendments, complex ...

Children with a rare form of cancer called neuroblastoma which hasn't responded to initial treatment or that has relapsed may benefit from adding antibody treatment to usual chemotherapy, according to ...

Children with a rare form of cancer called neuroblastoma which hasn’t responded to initial treatment or that has relapsed may benefit from adding antibody treatment to usual chemotherapy, according to ...

Beam Therapeutics (BEAM) announced new safety and efficacy data from its BEACON Phase 1/2 clinical trial of ristoglogene autogetemcel, formerly known as BEAM-101, an investigational genetically ...

CAMBRIDGE, Mass., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced new ...